Sorted By Test Name - Mayo Medical Laboratories

HEPB
200905
Profiles in Special Instructions.
Reference Values:
HEPATITIS Bs ANTIGEN
Negative
HEPATITIS Bc TOTAL ANTIBODY
Negative
HEPATITIS Be ANTIGEN
Negative
HEPATITIS Be ANTIBODY
Negative
HEPATITIS Bs ANTIBODY
HEPATITIS B SURFACE ANTIBODY
Unvaccinated: negative
Vaccinated: positive
HEPATITIS B SURFACE ANTIBODY, QUANTITATIVE
Unvaccinated: or =12.0
Interpretation depends on clinical setting.
See Viral Hepatitis Serologic Profiles in Special Instructions.
Clinical References: 1. Kubo S, Nishiguchi S, Hirohashi K, et al: Clinical significance of prior
hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999
September 1;86(5):793-798 2. Farrell G: Hepatitis B e antigen seroconversion: effects of lamivudine
alone on in combination with interferon alpha. J Med Virol 2000 July; 61(3):374-379 3. Schiff ER:
Lamivudine for hepatitis B in clinical practice. J Med Virol 2000 July;61(3):386-391 4. Sherlock S:
Hepatitis B: the disease. Vaccine 1990;8 Suppl:S6-S9
Hepatitis B Profile, Serum
Clinical Information: Hepatitis B is endemic throughout the world. The infection is spread primarily
through percutaneous contact with infected blood products, eg, blood transfusion, sharing of needles by
drug addicts. The virus is also found in virtually every type of human body fluid and has been known to
be spread through oral and genital contact. Hepatitis B virus (HBV) can be transmitted from mother to
child during delivery through contact with blood and vaginal secretions; it is not commonly transmitted
transplacentally.
Useful For: Determining whether a patient has been exposed to hepatitis B virus (HBV) Monitoring
patients recovering from HBV infection Diagnosis of HBV infection, although HBIS/209102 Hepatitis B
Immune Status Profile, Serum may be more conclusive
Interpretation: Presence of hepatitis B surface antigen (HBsAg) in serum may indicate acute hepatitis
B virus (HBV) infection, chronic HBV infection, or asymptomatic carrier state. The significance of
HBsAg in serum is determined by evaluating it in relationship to the presence or absence of the other
HBV markers and the clinical presentation and history of the patient. Before the onset of clinical illness,
HBsAg is detectable in the serum and its presence persists through the symptomatic phase of illness.
Following clinical illness, the titer of HBsAg begins to decline and eventually falls below a detectable
level. After HBsAg disappears, hepatitis B surface antibody (anti-HBs) appears in the serum, although
there is often a gap called the "window period" between the disappearance of HBsAg and the appearance
of anti-HBs. In approximately 10% of patients, HBsAg persists indefinitely in the serum, indicating a
chronic carrier state, and anti-HBs does not appear. During the course of a typical case of acute hepatitis
B infection, hepatitis B core antibody (anti-HBc) is present in the serum shortly before clinical symptoms
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 889